M

oderna Therapeutics, a private biotech firm worth a reported $7.5 billion, lost its head of vaccines just after the company raised $500 million on the promise of advancing vaccines into late-stage trials.

Giuseppe Ciaramella, who joined Moderna in 2014, left the company in February for a job at an early-stage biotech startup, according to people familiar with the matter. As chief scientific officer of Moderna’s vaccine business, Ciaramella managed the company’s most-advanced projects, authoring the firm’s journal publications and shepherding seven investigational vaccines into clinical trials.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy